Give Tommy a Headline!, page-39

@Armyne I would have no idea how to accurately value MSB but for me gut feel says a Company with over a $1 billion market cap operating for this length of time needs to have delivered something by now.

I recall reading in the AFR in around March/April this year that Mesoblast had raised over $1 billion in capital since listing in 2004. Nobody should be expecting instant results in the biotech/pharma space, but 17 years on Mesoblast are still churning out almost US$100m in losses, whilst getting asked more questions from the FDA, and delivering $7m revenue. I for one can’t fathom who would put more capital into this at the next raise (or why). But people have been doing it for 17 years, so maybe they’ll keep doing it…

It sure is an interesting company to follow from afar though.